Drug Profile
CIGB 500
Alternative Names: CIGB-500Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class Anti-ischaemics; Cytoprotectives; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cerebral ischaemia; Myocardial infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Myocardial-infarction(In volunteers) in Cuba (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-ischaemia in Cuba
- 12 May 2014 The Center for Genetic Engineering and Biotechnology plans a clinical trial for Myocardial infarction in Cuba (RPCEC00000177)